Search
for

    Learn

    5 / 801 results

      learn Finasteride

      Frontline, gold standard treatment for combatting androgenic alopecia

      learn Adenosine

      nucleoside used for hair regrowth stimulant properties

      learn Alfatradiol

      a synthetic estrogen used topically as an anti-androgen

      learn Dutasteride

      Heavy duty finasteride that comes with higher risks, but scalp injections seem safe and are gaining popularity

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results

      community Dim: high estradiol levels what to do

      in Chat  8 upvotes 1 year ago
      A user is experiencing facial bloating from low-dose topical finasteride due to high estradiol levels and is seeking advice on using DIM to manage this issue, including dosage and brand recommendations.

      community Estradiol mesotherapy / idea feedback

      in Female  6 upvotes 1 year ago
      The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.

      community Anagenic is trying to compound Gt20029

      in Treatment  56 upvotes 3 years ago
      The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

      community EMA is re-examining Winlevi (clascoterone at lower concentration)

      in Treatment  8 upvotes 11 months ago
      Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.